Recently, it has been shown that depletion of CHD4 sensitizes cancer cells to therapeutic agents (e.g. PARP inhibitors and DNMT inhibitors) in both hematopoietic and solid tumors (Cai et al., 2014; Nio et al., 2015; Sperlazza et al., 2015). This evidence concerns the gene CHD4 and cancer.